Predict your next investment

OMass Therapeutics company logo
HEALTHCARE | Drug Discovery
omass.com

See what CB Insights has to offer

Founded Year

2016

Stage

Series A - II | Alive

Total Raised

$53.83M

Last Raised

$35.83M | 2 yrs ago

About OMass Therapeutics

OMass Therapeutics is a biotechnology company that is focused on using structural mass spectrometry to discover medicines. It uses its suite of technologies based on high-resolution mass spectrometry to study intact protein assemblies.

OMass Therapeutics Headquarter Location

The Schrödinger Building Heatley Road, The Oxford Science Park

Oxford, England, OX4 4GE,

United Kingdom

01865-548350

Latest OMass Therapeutics News

YellowDog Accelerates Drug Discovery from One Year to Less Than One Day with a 162,120 Core Supercomputer, On-Demand

Sep 21, 2020

News provided by Share this article BRISTOL, England, Sept. 21, 2020 /CNW/ -- In drug discovery, as with many of the life sciences, data is key. The size of a dataset and the quality of the analyses has a powerful influence on the success of a given drug development programme. There is great potential for the cloud to aid drug discovery, as it offers companies the ability to dynamically scale their research and analyse more data than they would with their on-premise infrastructure. A graph to show the time it took to provision 2,000 instances using AWS. The blue circle represents the point at which all instances were running: within 10 minutes. (PRNewsfoto/YellowDog) OMass Therapeutics saw an opportunity to accelerate their virtual screening capabilities by utilising Harvard University's REAL database and YellowDog's multi-cloud workload management solution. With access to an on-demand supercomputer, OMass were able to dock 500 times more virtual compounds, and significantly enrich the top 10% of compounds screened. This top-level analysis enabled OMass to focus their attention on the most likely active molecules for their specific drug target. With a refined list of 477 million molecules for virtual screening, YellowDog delivered: YellowDog Sigma for fast provisioning and intelligent orchestration of 2,000 AWS spot instances, a total of 162,120 cores, across four regions. Task distribution and re-distribution. Integration with AutoDock Vina, an Open Source application for molecular docking. Secure storage and data retrieval using YellowDog Object Store. The outcomes are outstanding: The 477 million compounds were analysed and screened in 22.5 hours. Using OMass's existing setup, the same analyses would have taken one year. YellowDog Assura delivers a saving of 56.9% on the cloud compute costs for the workload. YellowDog Sigma provisioned the 2,000 AWS instances in 10 minutes. Using a standard scheduler or cloud provisioner would typically take 13 hours. The radical order change in the number of molecular docking analyses that are carried out at this early stage will help to significantly accelerate the time it takes OMass to identify lead compounds and bring life-changing benefits to patients. About OMass Therapeutics are an Oxford biotechnology company spun out of Oxford University harnessing native mass spectrometry and other biophysical technologies to drive drug discovery in high definition. YellowDog scale, control and optimise compute with their world-class hybrid- and multi-cloud workload management platform. YellowDog utilise the Best Source of Compute for customers' individual requirements so their workloads are delivered on time and on budget.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing OMass Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

OMass Therapeutics is included in 2 Expert Collections, including Pharma Startups.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

B

Biopharmaceuticals

5,732 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

OMass Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

OMass Therapeutics Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.